Osimertinib is a third-generation, irreversible oral EGFR-tyrosine kinase inhibitor), that
potently inhibits EGFR-tyrosine kinase inhibitor-sensitizing mutations and T790M resistance …

Importance To date, no meta-analyses have comprehensively assessed the association of
neoadjuvant chemoimmunotherapy with clinical outcomes in non–small cell lung cancer …

Lung cancer (LC) represents the second most diagnosed tumor and the malignancy with the
highest mortality rate. In recent years, tremendous progress has been made in the treatment …

Non-small-cell lung cancer (NSCLC) represents roughly 85% of lung cancers, with an
incidence that increases yearly across the world. The introduction in clinical practice of …

Despite remarkable treatment advancements in patients with advanced non–small cell lung
cancer (NSCLC), recurrence rates for those with resectable, early-stage disease remains …

The standard of care (SoC) for medically operable patients with early-stage (stage I–IIIB)
non-small cell lung cancer (NSCLC) is surgery combined with (neo) adjuvant systemic …

Simple Summary Tyrosine kinase inhibitors are drugs targeting the epidermal growth factor
receptor. In lung cancer, they are used to treat advanced EGFR-mutant diseases, and more …

The treatment of non-small-cell lung cancer (NSCLC) harbouring EGFR mutations has
witnessed some major breakthroughs in the last years. On the one hand, the recent advent …

Mesenchymal-epithelial transition (MET) exon 14 skipping mutation (METex14) is a low-
frequency driver mutation in metastatic NSCLC (3-4%) and associated with a poor …

Lung cancer continues to be the leading cause of cancer mortality and a serious health
problem despite the numerous advances made in the last decade and the rapid advance of …